Cargando…
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study
PF‐05221304 is a liver‐targeted inhibitor of acetyl‐CoA carboxylase, an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL). This first‐in‐human study investigated safety/tolerability and pharmacokinetics of single and multiple ascending oral PF‐05221304 doses, and fructose‐s...
Autores principales: | Bergman, Arthur, Carvajal‐Gonzalez, Santos, Tarabar, Sanela, Saxena, Aditi R., Esler, William P., Amin, Neeta B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317421/ https://www.ncbi.nlm.nih.gov/pubmed/32065514 http://dx.doi.org/10.1002/cpdd.782 |
Ejemplares similares
-
Acetyl-CoA Carboxylases and Diseases
por: Wang, Yu, et al.
Publicado: (2022) -
Chemical Genetics of Acetyl-CoA Carboxylases
por: Zu, Xuyu, et al.
Publicado: (2013) -
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
por: Ross, Trenton T., et al.
Publicado: (2020) -
The dynamic organization of fungal acetyl-CoA carboxylase
por: Hunkeler, Moritz, et al.
Publicado: (2016) -
Dynamics of the Degradation of Acetyl-CoA Carboxylase Herbicides in Vegetables
por: Jursík, Miroslav, et al.
Publicado: (2021)